Personal profile: Zhang Jiange, female, 1968, from Xinxiang, Henan, with no party affiliation, doctor. At present, he is a professor at the School of Pharmacy of Zhengzhou University, a tutor for master students, a deputy director of the Department of Medicinal Chemistry, and a standing member of the Professional Committee of Chinese Medicine Development and Cultivation of China Society of Chinese Medicine.

Bachelor of Pharmaceutical Chemistry, School of Pharmacy, West China University of Medical Sciences; Doctor of medicinal chemistry jointly trained by Fudan University and Shanghai Institute of Organic Science, Chinese Academy of Sciences; Postdoctoral student in medicinal chemistry jointly trained by Korea Institute of Chemistry; Postdoctoral students jointly trained by National University of Singapore and Yale University School of Medicine; Senior Research Fellow, Yale University School of Medicine.

Research direction: translational medicine research and innovative drug development of ischemic diseases or tumors related to angiogenesis; He has many years of experience in the research and teaching of medicinal chemistry, traditional Chinese medicine and natural medicine, medicine and molecular biology in universities in China and the United States, and has the ability to engage in translational medicine research. Completed the book "Medicinal Chemistry (Teaching Material for Examination of Compulsory Pharmacy Courses)" published by Science and Technology Literature Publishing House, and edited the fifth chapter separately.

achievements in scientific research

Several basic research projects funded by NIH in the United States were completed in Yale University Medical College, including "Mimed Mir- 1 is a regulator of angiogenesis in lung diseases". Interaction between immune/inflammatory cells and endothelial cells, molecular model of immune-mediated vascular injury.

The research direction is about the regulation of RNA binding protein on angiogenesis, which provides powerful scientific data for macrophages as primary inflammatory cells to release inflammatory factors in ischemic vascular diseases through the regulation of RNA binding protein on their mRNA stability, and then affects the formation of new blood vessels, and makes an important contribution to understanding the molecular biological mechanism of ischemic cardiovascular diseases. The research results are of pioneering significance for new methods to treat cardiovascular diseases.